Sino Biopharmaceutical(OTC) SBMFF

Sino Biopharmaceutical Limited is an integrated pharmaceutical enterprise focused on the research, development, manufacturing, and marketing of modernized Chinese and chemical medicines. The company primarily targets therapeutic areas such as oncology, liver disease, respiratory issues, and pain relief, with a strong market presence in mainland China.

Products and Services

• Wide range of modernized Chinese medicines
• Chemical medicines targeting various therapeutic areas
• Focus on oncology, liver disease, and respiratory treatments

Growth Outlook

• Revenue of CNY 9.72 billion in Q2 2026, indicating strong sales performance
• Operating income margin of 35.2% reflects efficient cost management
• Continued investment in R&D, with CNY 1.54 billion allocated in Q2 2026

Financial Highlights

• Net income of CNY 1.72 billion in Q2 2026, showcasing profitability
• Gross profit margin of 83.0% indicates strong pricing power
• Dividend yield of 2.15% offers attractive returns to shareholders

Sino Biopharmaceutical Limited has established itself as a key player in the pharmaceutical industry, particularly in the Chinese market. The company's commitment to research and development is evident in its significant investment, which supports innovation and product expansion. Recent financial performance highlights a robust revenue stream and profitability, making it an intriguing option for potential investors. The strong gross profit margin further underscores the company's ability to maintain competitive pricing while managing costs effectively. With a solid growth outlook and a focus on critical therapeutic areas, Sino Biopharmaceutical Limited presents a compelling opportunity in the healthcare sector.